7-hydroxystaurosporine has been researched along with Multiple Myeloma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almenara, JA; Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Venditti, CA | 1 |
| Cheson, BD | 1 |
| Dai, Y; Dent, P; Grant, S; Landowski, TH; Rosen, ST | 1 |
| Conrad, DH; Dai, Y; Dent, P; Grant, S; Pei, XY; Rahmani, M | 1 |
| Dai, Y; Dent, P; Grant, S; Li, W; Pei, XY; Rahmani, M | 1 |
| Dai, Y; Dent, P; Grant, S; Li, W; Pei, XY | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Khanna, P; Pei, XY | 1 |
| Dai, Y; Dent, P; Grant, S; Harada, H; Lu, J; Pei, XY; Tenorio, S | 1 |
1 review(s) available for 7-hydroxystaurosporine and Multiple Myeloma
| Article | Year |
|---|---|
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
7 other study(ies) available for 7-hydroxystaurosporine and Multiple Myeloma
| Article | Year |
|---|---|
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Checkpoint Kinase 1; DNA Damage; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Protein Kinase Inhibitors; Protein Kinases; Quinolones; ras Proteins; Staurosporine; Xenograft Model Antitumor Assays | 2008 |
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Topics: Alkaloids; Apoptosis; Benzamides; Bone Marrow Cells; CDC2 Protein Kinase; Cell Adhesion; Cell Cycle; Dexamethasone; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Free Radical Scavengers; Humans; Insulin-Like Growth Factor I; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Melphalan; Membrane Glycoproteins; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Neoplasm Proteins; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteoglycans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Staurosporine; Syndecan-1; Syndecans; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Humans; Intracellular Membranes; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-kappa B; Nitriles; Organic Chemicals; Proteoglycans; Staurosporine; Sulfones; Syndecan-1; Syndecans | 2004 |
The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Blotting, Western; CDC2 Protein Kinase; Cell Line, Tumor; Cytochromes c; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Glycogen Synthase Kinase 3; Humans; JNK Mitogen-Activated Protein Kinases; Methionine; Multiple Myeloma; Phosphorylation; Ribosomal Protein S6 Kinases, 70-kDa; STAT3 Transcription Factor; Staurosporine; Trans-Activators | 2005 |
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Topics: Apoptosis; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoint Kinase 1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Humans; Multiple Myeloma; Phosphorylation; Protein Kinases; RNA Interference; Staurosporine | 2006 |
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Topics: Cell Death; Drug Synergism; HL-60 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jurkat Cells; Leukemia; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Protein Prenylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Staurosporine; Transfection; Tumor Cells, Cultured; U937 Cells | 2007 |
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-X Protein; Benzamides; Blotting, Western; Drug Synergism; Enzyme Inhibitors; Humans; Immunoprecipitation; Insulin-Like Growth Factor I; Interleukin-6; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Multiple Myeloma; Phosphorylation; Protein Conformation; Protein Kinase C; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Staurosporine; Subcellular Fractions | 2007 |